Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
LSP Bioventures
AddedMar 19, 2024
UpdatedJun 28, 2026
LSP Bioventures

LSP Bioventures

Operating

Global investment in healthcare & life sciences sectors by Life Sciences Partners B.V. Serving US, Netherlands, Germany.

Location
Amsterdam, North Holland, NL
Founded
2006
Firm
Compare
Portfolio
Employees
Website

LSP BioVentures is a global venture capital fund specializing in the healthcare and life sciences sectors, with investments spanning the US, Netherlands, and Germany. The firm typically participates in Series A through Series D rounds, with a focus on innovative companies developing medicines, devices, and tools aimed at preserving health. Their investment sizes vary, with notable rounds ranging from $4 million to over $100 million.

LSP BioVentures boasts a diverse portfolio of nearly 200 companies, including prominent names like argenx, Cardiac Dimensions, and HotSpot Therapeutics. The firm is led by experienced partners who bring a wealth of industry knowledge and connections. Their investment philosophy centers on fostering long-term growth and innovation in the life sciences field. Additionally, LSP BioVentures offers value-added services such as strategic guidance and access to an extensive network of industry experts and co-investors.

LSP Bioventures - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments31
Current Portfolio Count16
Total Portfolio Exits1

Top Investment Stages

Series A11 (34.4%)
Series B10 (31.3%)
Series C5 (15.6%)
Series D3 (9.4%)
Series Unknown3 (9.4%)

Stage Mix

Series A 34%Series B 31%Series C 16%Series D 9%Series Unknown 9%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Shinobi Therapeutics logo

Shinobi Therapeutics

Evommune logo

Evommune

QurAlis logo

QurAlis

HotSpot Therapeutics logo

HotSpot Therapeutics

Visus Therapeutics logo

Visus Therapeutics

Xilis logo

Xilis

XyloCor Therapeutics logo

XyloCor Therapeutics

Cardiac Dimensions logo

Cardiac Dimensions

Lumeon logo

Lumeon

Endotronix logo

Endotronix

Rainier Therapeutics logo

Rainier Therapeutics

Harvest Automation logo

Harvest Automation

Cobalt Technologies logo

Cobalt Technologies

argenx logo

argenx

Trinity Biosystems logo

Trinity Biosystems

Asoyia logo

Asoyia

Efficas logo

Efficas

Scion Pharmaceuticals logo

Scion Pharmaceuticals

LSP Bioventures - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end